Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400463 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02400463 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT02400463, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a pilot study to determine the efficacy of Ruxolitinib in secondary hemophagocytic syndrome. The primary objective is to assess the efficacy of ruxolitinib 15 mg PO twice daily in patients with HPS. The primary endpoint is overall survival at two months.
Interventions
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-02-05 |
| Est. Completion | 2020-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02400463
The ClinicalTrials.gov registry entry for NCT02400463 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT02400463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02400463 about?
NCT02400463 is a clinical study titled "A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome". This is a pilot study to determine the efficacy of Ruxolitinib in secondary hemophagocytic syndrome. The primary objective is to assess the efficacy of ruxolitinib 15 mg PO twice daily in patients with HPS. The primary endpoint is overall survival at two months.
What is the current status of trial NCT02400463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2016-02-05. Estimated completion is 2020-01-07.
What interventions are being tested in trial NCT02400463?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02400463?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.